歸創通橋-B(02190.HK)與廣東海思卡爾達成戰略合作 豐富公司在泛血管介入通路產品組合
格隆匯4月20日丨歸創通橋-B(02190.HK)宣佈,為豐富公司在泛血管介入通路產品組合,公司已與中國創新醫療器械公司廣東海思卡爾醫療科技有限公司("廣東海思卡爾",為公司的獨立第三方)訂立戰略合作協議,從而於中國推廣及銷售外周血管介入及神經血管介入導絲產品。公司的外周血管介入事業部浙江歸創醫療將陸續推出"歸創—海思導絲家族"產品,滿足從造影診斷到狹窄、中重度鈣化及完全閉塞病變等疾病的開通和治療的各種臨牀需求。
公司的神經血管介入事業部珠海通橋醫療通過自主研發及聯合廣東海思卡爾共同推出北斗系列微導絲,可滿足缺血性及出血性腦卒中的不同臨牀治療需求。導絲是血管介入手術中最基本的工具之一。性能優異的導絲產品可為介入手術提供更安全、更高效的手術體驗,減少手術併發症的發生。根據行業估計數字,中國的神經介入手術數量估計將從2019年的15.96萬台增至2030年的178.10萬台,2019年至2030年的年複合增長率為24.5%,以及據估計,中國的外周動脈介入手術數量將從2019年的11.22萬台增到2030年的60.01萬台,2019年至2030年的年複合增長率為16.5%。監於較高的技術壁壘及器械使用習慣的影響,中國介入導絲市場仍由跨國公司主導。血管介入手術滲透率的提高有望拉動導絲的需求,我們認為國內製造商爭奪市場份額的潛力巨大。
與廣東海思卡爾的合作代表了我們為豐富產品組合和加速實現為患者和醫生提供全面治療解決方案的目標的多元化的策略。公司相信,與中國乃至全球優質醫療公司的戰略合作將是其未來重要的增長動力之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.